{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:32:23Z","timestamp":1790310743459,"version":"4.1.0"},"reference-count":43,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Stroke"],"published-print":{"date-parts":[[2002,7]]},"abstract":"<jats:p>\n            <jats:bold>\n              <jats:italic>\n                <jats:bold>\n                  <jats:italic>Background and Purpose<\/jats:italic>\n                <\/jats:bold>\n                \u2014\n              <\/jats:italic>\n            <\/jats:bold>\n            Based on the hypothesis of glutamate-induced neurotoxicity (excitotoxicity) in cerebral ischemia, this study examined the efficacy and tolerability of memantine, an uncompetitive\n            <jats:italic>N<\/jats:italic>\n            -methyl-\n            <jats:sc>d<\/jats:sc>\n            -aspartate antagonist, in the treatment of mild to moderate vascular dementia.\n          <\/jats:p>\n          <jats:p>\n            <jats:bold>\n              <jats:italic>\n                <jats:bold>\n                  <jats:italic>Methods<\/jats:italic>\n                <\/jats:bold>\n                \u2014\n              <\/jats:italic>\n            <\/jats:bold>\n            In this multicenter, 28-week trial carried out in France, 321 patients received 10 mg\/d memantine or placebo twice a day; 288 patients were valid for intent-to-treat analysis. Patients had to meet the criteria for probable vascular dementia and have a Mini-Mental State (MMSE) score between 12 and 20 at inclusion. The 2 primary end points were the cognitive subscale of the Alzheimers Disease Assessment Scale (ADAS-cog) and the global Clinician\u2019s Interview Based Impression of Change (CIBIC-plus).\n          <\/jats:p>\n          <jats:p>\n            <jats:bold>\n              <jats:italic>\n                <jats:bold>\n                  <jats:italic>Results<\/jats:italic>\n                <\/jats:bold>\n                \u2014\n              <\/jats:italic>\n            <\/jats:bold>\n            After 28 weeks, the mean ADAS-cog scores were significantly improved relative to placebo. In the intention-to-treat population, the memantine group mean score had gained an average of 0.4 points, whereas the placebo group mean score had declined by 1.6 points, ie, a difference of 2.0 points (95% confidence interval, 0.49 to 3.60). The response rate for CIBIC-plus, defined as improved or stable, was 60% with memantine compared with 52% with placebo (\n            <jats:italic>P<\/jats:italic>\n            =0.227, intention to treat). Among the secondary efficacy parameters, which were analyzed in the per-protocol subset, MMSE was significantly improved with memantine compared with deterioration with placebo (\n            <jats:italic>P<\/jats:italic>\n            =0.003). The Gottfries-Brane-Steen Scale intellectual function subscore and the Nurses\u2019 Observation Scale for Geriatric Patients disturbing behavior dimension also showed differences in favor of memantine (\n            <jats:italic>P<\/jats:italic>\n            =0.04 and\n            <jats:italic>P<\/jats:italic>\n            =0.07, respectively). Memantine was well tolerated with a frequency of adverse events comparable to placebo.\n          <\/jats:p>\n          <jats:p>\n            <jats:bold>\n              <jats:italic>\n                <jats:bold>\n                  <jats:italic>Conclusions<\/jats:italic>\n                <\/jats:bold>\n                \u2014\n              <\/jats:italic>\n            <\/jats:bold>\n            In patients with mild to moderate vascular dementia, memantine 20 mg\/d improved cognition consistently across different cognitive scales, with at least no deterioration in global functioning and behavior. It was devoid of concerning side effects.\n          <\/jats:p>","DOI":"10.1161\/01.str.0000020094.08790.49","type":"journal-article","created":{"date-parts":[[2002,7,28]],"date-time":"2002-07-28T23:16:47Z","timestamp":1027898207000},"page":"1834-1839","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":407,"title":["Efficacy and Safety of Memantine in Patients With Mild to Moderate Vascular Dementia"],"prefix":"10.1161","volume":"33","author":[{"given":"Jean-Marc","family":"Orgogozo","sequence":"first","affiliation":[{"name":"From CHU Pellegrin, Bordeaux, France (J.-M.O.); Ho\u0302pital Broca, Paris, France (A.-S.R., F.F.); and Merz Pharmaceuticals, Frankfurt, Germany (A.S., H.-J.M.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Sophie","family":"Rigaud","sequence":"additional","affiliation":[{"name":"From CHU Pellegrin, Bordeaux, France (J.-M.O.); Ho\u0302pital Broca, Paris, France (A.-S.R., F.F.); and Merz Pharmaceuticals, Frankfurt, Germany (A.S., H.-J.M.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albrecht","family":"Sto\u0308ffler","sequence":"additional","affiliation":[{"name":"From CHU Pellegrin, Bordeaux, France (J.-M.O.); Ho\u0302pital Broca, Paris, France (A.-S.R., F.F.); and Merz Pharmaceuticals, Frankfurt, Germany (A.S., H.-J.M.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Jorgen","family":"Mo\u0308bius","sequence":"additional","affiliation":[{"name":"From CHU Pellegrin, Bordeaux, France (J.-M.O.); Ho\u0302pital Broca, Paris, France (A.-S.R., F.F.); and Merz Pharmaceuticals, Frankfurt, Germany (A.S., H.-J.M.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franc\u0327oise","family":"Forette","sequence":"additional","affiliation":[{"name":"From CHU Pellegrin, Bordeaux, France (J.-M.O.); Ho\u0302pital Broca, Paris, France (A.-S.R., F.F.); and Merz Pharmaceuticals, Frankfurt, Germany (A.S., H.-J.M.)."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_3_1_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.312.7025.227"},{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0306-4522(93)90355-J"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-1166(199901)14:1<3::AID-GPS897>3.0.CO;2-7"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(96)00047-9"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0079-6123(08)60446-X"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0197-4580(89)90143-7"},{"key":"e_1_3_3_7_2","first-page":"597","volume":"50","year":"1998","unstructured":"Danysz W, Parsons CG. Glycine and N-methyl-d-aspartate receptors: physiological significance and possible therapeutic applications. Pharmacol Rev. 1998; 50: 597\u2013664.","journal-title":"Pharmacol Rev"},{"key":"e_1_3_3_8_2","first-page":"91","volume":"43","year":"1994","unstructured":"Kornhuber J, Weller M, Schoppmeyer K, Riederer P. Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. J Neural Transm Suppl. 1994; 43: 91\u2013104.","journal-title":"J Neural Transm Suppl"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0028-3908(99)00019-2"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1460-9568.1996.tb01241.x"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(95)00716-4"},{"key":"e_1_3_3_12_2","first-page":"117","volume":"46","year":"1995","unstructured":"Heim C, Sontag KH. Memantine prevents progressive functional neurodegeneration in rats. J Neural Transm Suppl. 1995; 46: 117\u2013130.","journal-title":"J Neural Transm Suppl"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0028-3908(99)00168-9"},{"key":"e_1_3_3_14_2","first-page":"773","volume":"41","year":"1991","unstructured":"Ditzler K. Efficacy and tolerability of memantine in patients with dementia syndrome. Drug Res. 1991; 41: 773\u2013780.","journal-title":"Drug Res"},{"key":"e_1_3_3_15_2","first-page":"904","volume":"42","year":"1992","unstructured":"G\u00f6rtelmeyer R, Erbler H. Memantine in the treatment of mild to moderate dementia syndrome: a double-blind placebo-controlled study. Arzneimittelforschung. 1992; 42: 904\u2013913.","journal-title":"Arzneimittelforschung"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-1166(199902)14:2<135::AID-GPS906>3.0.CO;2-0"},{"key":"e_1_3_3_17_2","first-page":"S275.","volume":"21","year":"2000","unstructured":"Reisberg B, Windscheif U, Ferris SH, Hingorani VH, Stoeffler A, Moebius HJ. Memantine in moderately severe to severe Alzheimer\u2019s disease (AD): results of a placebo-controlled 6-month trial. Neurobiol Aging. 2000; 21 (1S): S275.Abstract.","journal-title":"Neurobiol Aging"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.9.6.1397"},{"key":"e_1_3_3_19_2","first-page":"S172","volume":"13","year":"1999","unstructured":"M\u00f6bius HJ. Pharmacological rationale for memantine in chronic cerebral hypoperfusion, especially vascular dementia. Alzheimer Dis Assoc Disord. 1999; 13 (suppl 3): S172\u2013S178.","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.43.2.250"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1161\/str.14.3.6658909"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.49.3.690"},{"key":"e_1_3_3_23_2","unstructured":"DSM-III-R: Diagnostic and Statistical Manual of Mental Disorders Rev 3rd ed. Washington DC: American Psychiatric Association; 1987: 102\u2013123."},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-3956(75)90026-6"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.34.7.939"},{"key":"e_1_3_3_26_2","first-page":"448","volume":"19","year":"1983","unstructured":"Mohs RC, Rosen WG, Davis KL. The Alzheimer\u2019s Disease Assessment Scale: an instrument for assessing treatment efficacy. Psychopharmacol Bull. 1983; 19: 448\u201350.","journal-title":"Psychopharmacol Bull"},{"key":"e_1_3_3_27_2","first-page":"627","volume":"24","year":"1988","unstructured":"Mohs RC, Cohen L. Alzheimer\u2019s Disease Assessment Scale (ADAS). Psychopharmacol Bull. 1988; 24: 627\u2013450.","journal-title":"Psychopharmacol Bull"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002093-199706001-00003"},{"key":"e_1_3_3_29_2","unstructured":"Gottfries CG Brane G Steen B GBS Scale. In. Israel L Kozarevic D Sartorius N eds. Source Book of Geriatric Assessment. 1st ed. Basel Switzerland: S. Karger; 1982: 259\u2013260."},{"key":"e_1_3_3_30_2","doi-asserted-by":"crossref","unstructured":"Guy W. 028. CGI: clinical global impressions.In: Guy W ed. ECDEU Assessment Manual for Psychopharmacology.Rev ed. Rockville Md: National Institutes of Health; 1976: 217\u2013220.","DOI":"10.1037\/e591322011-001"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.1991.tb02897.x"},{"key":"e_1_3_3_32_2","first-page":"23","volume":"59","year":"2000","unstructured":"Erkinjuntti T, Inzitari D, Pantoni L, Wallin A, Scheltens P, Rockwood K, Roman GC, Chui H, Desmond DW. Research criteria for subcortical vascular dementia in clinical trials. J Neural Transm Suppl. 2000; 59: 23\u201330.","journal-title":"J Neural Transm Suppl"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2000.tb06412.x"},{"key":"e_1_3_3_34_2","first-page":"S219.","volume":"19","year":"1998","unstructured":"Jellinger KA. Vascular dementia: disease entity or Alzheimer type lesion? Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Neurobiol Aging. 1998; 19 (4S): S219.Abstract.","journal-title":"Neurobiol Aging"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002093-199912003-00017"},{"key":"e_1_3_3_36_2","first-page":"S140","volume":"13","year":"1999","unstructured":"Ferris SH. Cognitive outcome measures. Alzheimer Dis Assoc Disord. 1999; 13 (suppl 3): S140\u2013S143.","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"e_1_3_3_37_2","first-page":"S21","volume":"13","year":"1999","unstructured":"Desmond DW, Erkinjuntti T, Sano M, Cummings JL, Bowler J V, Pasquier F, Moroney JT, Ferris SH, Stern Y, Sachdev PS, Hachinski VC. The cognitive syndrome of vascular dementia: implications for clinical trials. Alzheimer Dis Assoc Disord. 1999; 13 (suppl 3): S21\u2013S29.","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.50.1.136"},{"key":"e_1_3_3_39_2","first-page":"633","volume":"318","year":"1999","unstructured":"R\u00f6sler M, Anand R, Cincin-Sain A, for the B303 Exelon Study Group. Efficacy and safety of rivastigmine in patients with Alzheimer\u2019s disease: results of an international, 26-week, multicenter, randomized placebo-controlled trial. BMJ. 1999; 318: 633\u2013638.","journal-title":"BMJ"},{"key":"e_1_3_3_40_2","first-page":"S166","volume":"13","year":"1999","unstructured":"Kittner B. Clinical trials of propentofylline in vascular dementia: European\/Canadian Propentofylline Study Group. Alzheimer Dis Assoc Disord. 1999; 13 (suppl 3): S166\u2013S171.","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-510X(00)00301-4"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.9.6.1397"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2000-341"}],"container-title":["Stroke"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/01.STR.0000020094.08790.49","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,12]],"date-time":"2024-05-12T20:31:01Z","timestamp":1715545861000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/01.STR.0000020094.08790.49"}},"subtitle":["A Randomized, Placebo-Controlled Trial (MMM 300)"],"short-title":[],"issued":{"date-parts":[[2002,7]]},"references-count":43,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2002,7]]}},"alternative-id":["10.1161\/01.STR.0000020094.08790.49"],"URL":"https:\/\/doi.org\/10.1161\/01.str.0000020094.08790.49","relation":{},"ISSN":["0039-2499","1524-4628"],"issn-type":[{"value":"0039-2499","type":"print"},{"value":"1524-4628","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,7]]},"assertion":[{"value":"2001-12-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2002-04-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2002-07-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}